Schizophrenia Research
Volume 86, Issue 1 , Pages 1-14 , September 2006

Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability

Received 24 October 2005 ,Revised 22 May 2006 ,Accepted 27 May 2006.

References 

  1. Altar CA, Jurata LW, Charles V, Lemire A, Liu P, Bukhman Y, et al. Deficient hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial genes in multiple schizophrenia cohorts. Biol. Psychiatry. 2005;58:85–96
  2. Angelastro JM, Mason JL, Ignatova TN, Kukekov VG, Stengren GB, Goldman JE, et al. Downregulation of activating transcription factor 5 is required for differentiation of neural progenitor cells into astrocytes. J. Neurosci. 2005;25:3889–3899
  3. Back SA, Gan X, Li Y, Rosenberg PA, Volpe JJ. Maturation-dependent vulnerability of oligodendrocytes to oxidative stress-induced death caused by glutathione depletion. J. Neurosci. 1998;18:6241–6253
  4. Bamford NS, Zhang H, Schmitz Y, Wu NP, Cepeda C, Levine MS, et al. Heterosynaptic dopamine neurotransmission selects sets of corticostriatal terminals. Neuron. 2004;42:653–663
  5. Bashir ZI, Alford S, Davies SN, Randall AD, Collingridge GL. Long-term potentiation of NMDA receptor-mediated synaptic transmission in the hippocampus. Nature. 1991;349:156–158
  6. Becker KG, Barnes KC, Bright TJ, Wang SA. The genetic association database. Nat. Genet. 2004;36:431–432
  7. Black JE, Kodish IM, Grossman AW, Klintsova AY, Orlovskaya D, Vostrikov V, et al. Pathology of layer V pyramidal neurons in the prefrontal cortex of patients with schizophrenia. Am. J. Psychiatry. 2004;161:742–744
  8. Brenman JE, Bredt DS. Synaptic signaling by nitric oxide. Curr. Opin. Neurobiol. 1997;7:374–378
  9. Brown JS. Geographic correlation of schizophrenia to ticks and tick-borne encephalitis. Schizophr. Bull. 1994;20:755–775
  10. Brown AS. Prenatal infection as a risk factor for schizophrenia. Schizophr. Bull. 2006;
  11. Calakos N, Scheller RH. Synaptic vesicle biogenesis, docking, and fusion: a molecular description. Physiol. Rev. 1996;76:1–29
  12. Cannon TD. The inheritance of intermediate phenotypes for schizophrenia. Curr. Opin. Psychiatry. 2005;18:135–140
  13. Carlsson A, Waters N, Hansson O. Neurotransmitter aberrations in schizophrenia: new findings. In:  Fog R,  Gerlach R,  Hemmingen R editor. Schizophrenia, Alfred Benzon Symposium. vol. 38:Copenhagen: Munksgaard; 1994;
  14. Carter CJ. Polygenic signaling pathways. 2006;http://www.polygenicpathways.co.uk. Website. Ref Type: Electronic Citation
  15. Chen A, Muzzio IA, Malleret G, Bartsch D, Verbitsky M, Pavlidis P, et al. Inducible enhancement of memory storage and synaptic plasticity in transgenic mice expressing an inhibitor of ATF4 (CREB-2) and C/EBP proteins. Neuron. 2003;39:655–669
  16. Chiba S, Hashimoto R, Hattori S, Yohda M, Lipska B, Weinberger DR, et al. Effect of antipsychotic drugs on DISC1 and dysbindin expression in mouse frontal cortex and hippocampus. J. Neural Transm. 2006;
  17. Chotai J, Serretti A, Lorenzi C. Interaction between the tryptophan hydroxylase gene and the serotonin transporter gene in schizophrenia but not in bipolar or unipolar affective disorders. Neuropsychobiology. 2005;51:3–9
  18. Chumakov I, Blumenfeld M, Guerassimenko O, Cavarec L, Palicio M, Abderrahim H, et al. Genetic and physiological data implicating the new human gene G72 and the gene for d-amino acid oxidase in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2002;99:13675–13680
  19. Collin C, Miyaguchi K, Segal M. Dendritic spine density and LTP induction in cultured hippocampal slices. J. Neurophysiol. 1997;77:1614–1623
  20. Coyle JT, Tsai G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl). 2004;174:32–38
  21. Davis JO, Bracha HS. Famine and schizophrenia: first-trimester malnutrition or second-trimester beriberi. Biol. Psychiatry. 1996;40:1–3
  22. Davies SN, Lester RA, Reymann KG, Collingridge GL. Temporally distinct pre- and post-synaptic mechanisms maintain long-term potentiation. Nature. 1989;338:500–503
  23. DeLisi LE, Faraone SV. When is a “positive” association truly a “positive” in psychiatric genetics?. Am. J. Med. Genet. 2006;141:319–322
  24. Di Stasi AM, Mallozzi C, Macchia G, Maura G, Petrucci TC, Minetti M. Peroxynitrite affects exocytosis and SNARE complex formation and induces tyrosine nitration of synaptic proteins. J. Neurochem. 2002;82:420–429
  25. Do KQ, Trabesinger AH, Kirsten-Kruger M, Lauer CJ, Dydak U, Hell D, et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur. J. Neurosci. 2000;12:3721–3728
  26. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2001;98:6917–6922
  27. Feliciello A, Cardone L, Garbi C, Ginsberg MD, Varrone S, Rubin CS, et al. Yotiao protein, a ligand for the NMDA receptor, binds and targets cAMP-dependent protein kinase II(1). FEBS Lett. 1999;464:174–178
  28. Flores AI, Mallon BS, Matsui T, Ogawa W, Rosenzweig A, Okamoto T, et al. Akt-mediated survival of oligodendrocytes induced by neuregulins. J. Neurosci. 2000;20:7622–7630
  29. Flynn SW, Lang DJ, Mackay AL, Goghari V, Vavasour IM, Whittall KP, et al. Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins. Mol. Psychiatry. 2003;8:811–820
  30. Gallinat J, Bajbouj M, Sander T, Schlattmann P, Xu K, Ferro EF, et al. Association of the G1947A COMT (Val(108/158)Met) gene polymorphism with prefrontal P300 during information processing. Biol. Psychiatry. 2003;54:40–48
  31. Gandhi TK, Zhong J, Mathivanan S, Karthick L, Chandrika KN, Mohan SS, et al. Analysis of the human protein interactome and comparison with yeast, worm and fly interaction datasets. Nat. Genet. 2006;38:285–293
  32. Garey LJ, Ong WY, Patel TS, Kanani M, Davis A, Mortimer AM, et al. Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. J. Neurol. Neurosurg. Psychiatry. 1998;65:446–453
  33. Gerecke KM, Wyss JM, Carroll SL. Neuregulin-1beta induces neurite extension and arborization in cultured hippocampal neurons. Mol. Cell. Neurosci. 2004;27:379–393
  34. Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch. Gen. Psychiatry. 2000;57:65–73
  35. Goldman-Rakic PS, Selemon LD. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr. Bull. 1997;23:437–458
  36. Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV. Targeting the dopamine D(1) receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl). 2004;174:3–16
  37. Goldshmit Y, Erlich S, Pinkas-Kramarski R. Neuregulin rescues PC12-ErbB4 cells from cell death induced by H(2)O(2). Regulation of reactive oxygen species levels by phosphatidylinositol 3-kinase. J. Biol. Chem. 2001;276:46379–46385
  38. Gu Z, Jiang Q, Fu AK, Ip NY, Yan Z. Regulation of NMDA receptors by neuregulin signaling in prefrontal cortex. J. Neurosci. 2005;25:4974–4984
  39. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2001;98:4746–4751
  40. Harding HP, Zhang Y, Zeng H, Novoa I, Lu PD, Calfon M, et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol. Cell. 2003;11:619–633
  41. Harrison PJ, Owen MJ. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet. 2003;361:417–419
  42. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry. 2005;10:40–68
  43. He CH, Gong P, Hu B, Stewart D, Choi ME, Choi AM, et al. Identification of activating transcription factor 4 (ATF4) as an Nrf2-interacting protein. Implication for heme oxygenase-1 gene regulation. J. Biol. Chem. 2001;276:20858–20865
  44. Hennecke J, Wiley DC. Structure of a complex of the human alpha/beta T cell receptor (TCR) HA1.7, influenza hemagglutinin peptide, and major histocompatibility complex class II molecule, HLA-DR4 (DRA⁎0101 and DRB1⁎0401): insight into TCR cross-restriction and alloreactivity. J. Exp. Med. 2002;195:571–581
  45. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet. Med. 2002;4:45–61
  46. Hof PR, Haroutunian V, Copland C, Davis KL, Buxbaum JD. Molecular and cellular evidence for an oligodendrocyte abnormality in schizophrenia. Neurochem. Res. 2002;27:1193–1200
  47. Hof PR, Haroutunian V, Friedrich VL, Byne W, Buitron C, Perl DP, et al. Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol. Psychiatry. 2003;53:1075–1085
  48. Huang G, Dragan M, Freeman D, Wilson JX. Activation of catechol-O-methyltransferase in astrocytes stimulates homocysteine synthesis and export to neurons. Glia. 2005;51:47–55
  49. Iwamoto K, Bundo M, Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum. Mol. Genet. 2005;14:241–253
  50. Jaffrey SR, Snowman AM, Eliasson MJ, Cohen NA, Snyder SH. CAPON: a protein associated with neuronal nitric oxide synthase that regulates its interactions with PSD95. Neuron. 1998;20:115–124
  51. Jaffrey SR, Benfenati F, Snowman AM, Czernik AJ, Snyder SH. Neuronal nitric-oxide synthase localization mediated by a ternary complex with synapsin and CAPON. Proc. Natl. Acad. Sci. U. S. A. 2002;99:3199–3204
  52. Johnstone EC, Crow TJ, Frith CD, Husband J, Kreel L. Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet. 1976;2:924–926
  53. Kalivas PW, Duffy P. Dopamine regulation of extracellular glutamate in the nucleus accumbens. Brain Res. 1997;761:173–177
  54. Kampman O, Anttila S, Illi A, Mattila KM, Rontu R, Leinonen E, et al. Interaction of tumor necrosis alpha-G308A and epidermal growth factor gene polymorphisms in early-onset schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2005;255:279–283
  55. Katsel P, Davis KL, Haroutunian V. Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: a gene ontology study. Schizophr. Res. 2005;
  56. Katsel P, Davis KL, Haroutunian V. Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: a gene ontology study. Schizophr. Res. 2005;
  57. Kerns JM, Sierens DK, Kao LC, Klawans HL, Carvey PM. Synaptic plasticity in the rat striatum following chronic haloperidol treatment. Clin Neuropharmacol. 1992;15:488–500
  58. Khorchid A, Fragoso G, Shore G, Almazan G. Catecholamine-induced oligodendrocyte cell death in culture is developmentally regulated and involves free radical generation and differential activation of caspase-3. Glia. 2002;40:283–299
  59. Knable MB, Torrey EF, Webster MJ, Bartko JJ. Multivariate analysis of prefrontal cortical data from the Stanley Foundation Neuropathology Consortium. Brain Res. Bull. 2001;55:651–659
  60. Kung L, Conley R, Chute DJ, Smialek J, Roberts RC. Synaptic changes in the striatum of schizophrenic cases: a controlled postmortem ultrastructural study. Synapse. 1998;28:125–139
  61. Laruelle M, Kegeles LS, Abi-Dargham A. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann. N. Y. Acad. Sci. 2003;1003:138–158
  62. Lee FJ, Xue S, Pei L, Vukusic B, Chery N, Wang Y, et al. Dual regulation of NMDA receptor functions by direct protein–protein interactions with the dopamine D1 receptor. Cell. 2002;111:219–230
  63. Lee JM, Calkins MJ, Chan K, Kan YW, Johnson JA. Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J. Biol. Chem. 2003;278:12029–12038
  64. Lee JM, Shih AY, Murphy TH, Johnson JA. NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons. J. Biol. Chem. 2003;278:37948–37956
  65. Lee JT, Xu J, Lee JM, Ku G, Han X, Yang DI, et al. Amyloid-{beta} peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J. Cell Biol. 2004;164:123–131
  66. Lewis DA, Volk DW, Hashimoto T. Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology (Berl). 2004;174:143–150
  67. Liu W, Breen G, Zhang J, Li S, Gu N, Feng G, et al. Association of APOE gene with schizophrenia in Chinese: a possible risk factor in times of malnutrition. Schizophr. Res. 2003;62:225–230
  68. Mahadik SP, Scheffer RE. Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins Leukot. Essent. Fat. Acids. 1996;55:45–54
  69. Mason JL, Angelastro JM, Ignatova TN, Kukekov VG, Lin G, Greene LA, et al. ATF5 regulates the proliferation and differentiation of oligodendrocytes. Mol. Cell. Neurosci. 2005;29:372–380
  70. Millar JK, Wilson-Annan JC, Anderson S, Christie S, Taylor MS, Semple CA, et al. Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum. Mol. Genet. 2000;9:1415–1423
  71. Millar JK, Christie S, Porteous DJ. Yeast two-hybrid screens implicate DISC1 in brain development and function. Biochem. Biophys. Res. Commun. 2003;311:1019–1025
  72. Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron. 2000;28:53–67
  73. Miyoshi K, Honda A, Baba K, Taniguchi M, Oono K, Fujita T, et al. Disrupted-in-schizophrenia 1, a candidate gene for schizophrenia, participates in neurite outgrowth. Mol. Psychiatry. 2003;8:685–694
  74. Morris JA, Kandpal G, Ma L, Austin CP. DISC1 (Disrupted-In-Schizophrenia 1) is a centrosome-associated protein that interacts with MAP1A, MIPT3, ATF4/5 and NUDEL: regulation and loss of interaction with mutation. Hum. Mol. Genet. 2003;12:1591–1608
  75. Nepom GT, Domeier ME, Ou D, Kovats S, Mitchell LA, Tingle AJ. Recognition of contiguous allele-specific peptide elements in the rubella virus E1 envelope protein. Vaccine. 1997;15:648–652
  76. Norton N, Moskvina V, Morris DW, Bray NJ, Zammit S, Williams NM, et al. Evidence that interaction between neuregulin 1 and its receptor erbB4 increases susceptibility to schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005;
  77. Owen MJ. Genomic approaches to schizophrenia. Clin. Ther. 2005;27(Suppl A):S2–S7
  78. Paintlia MK, Paintlia AS, Barbosa E, Singh I, Singh AK. N-acetylcysteine prevents endotoxin-induced degeneration of oligodendrocyte progenitors and hypomyelination in developing rat brain. J. Neurosci. Res. 2004;78:347–361
  79. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JJ, Griffin JL, et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry. 2004;9:684–697
  80. Qin S, Zhao X, Pan Y, Liu J, Feng G, Fu J, et al. An association study of the N-methyl-d-aspartate receptor NR1 subunit gene (GRIN1) and NR2B subunit gene (GRIN2B) in schizophrenia with universal DNA microarray. Eur. J. Hum. Genet. 2005;13:807–814
  81. Rameau GA, Chiu LY, Ziff EB. NMDA receptor regulation of nNOS phosphorylation and induction of neuron death. Neurobiol. Aging. 2003;24:1123–1133
  82. Rapoport JL, Addington AM, Frangou S, Psych MR. The neurodevelopmental model of schizophrenia: update 2005. Mol. Psychiatry. 2005;
  83. Reddy RD, Yao JK. Free radical pathology in schizophrenia: a review. Prostaglandins Leukot. Essent. Fat. Acids. 1996;55:33–43
  84. Richter-Landsberg C, Vollgraf U. Mode of cell injury and death after hydrogen peroxide exposure in cultured oligodendroglia cells. Exp. Cell Res. 1998;244:218–229
  85. Rosenberg PA, Li Y, Ali S, Altiok N, Back SA, Volpe JJ. Intracellular redox state determines whether nitric oxide is toxic or protective to rat oligodendrocytes in culture. J. Neurochem. 1999;73:476–484
  86. Rosin C, Bates TE, Skaper SD. Excitatory amino acid induced oligodendrocyte cell death in vitro: receptor-dependent and -independent mechanisms. J. Neurochem. 2004;90:1173–1185
  87. Rosoklija G, Toomayan G, Ellis SP, Keilp J, Mann JJ, Latov N, et al. Structural abnormalities of subicular dendrites in subjects with schizophrenia and mood disorders: preliminary findings. Arch. Gen. Psychiatry. 2000;57:349–356
  88. Rutkowski DT, Kaufman RJ. All roads lead to ATF4. Dev. Cell. 2003;4:442–444
  89. Rybakowski JK, Borkowska A, Czerski PM, Hauser J. Eye movement disturbances in schizophrenia and a polymorphism of catechol-O-methyltransferase gene. Psychiatry Res. 2002;113:49–57
  90. Sanchez-Perez AM, Llansola M, Felipo V. Modulation of NMDA receptors by AKT kinase. Neurochem. Int. 2006;
  91. Selemon LD, Goldman-Rakic PS. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol. Psychiatry. 1999;45:17–25
  92. Shi SH, Hayashi Y, Petralia RS, Zaman SH, Wenthold RJ, Svoboda K, et al. Rapid spine delivery and redistribution of AMPA receptors after synaptic NMDA receptor activation. Science. 1999;284:1811–1816
  93. Steere AC, Falk B, Drouin EE, Baxter-Lowe LA, Hammer J, Nepom GT. Binding of outer surface protein A and human lymphocyte function-associated antigen 1 peptides to HLA-DR molecules associated with antibiotic treatment-resistant Lyme arthritis. Arthritis Rheum. 2003;48:534–540
  94. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, et al. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 2002;71:877–892
  95. Straub RE, Jiang Y, MacLean CJ, Ma Y, Webb BT, Myakishev MV, et al. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am. J. Hum. Genet. 2002;71:337–348
  96. Sugai T, Kawamura M, Iritani S, Araki K, Makifuchi T, Imai C, et al. Prefrontal abnormality of schizophrenia revealed by DNA microarray: impact on glial and neurotrophic gene expression. Ann. N. Y. Acad. Sci. 2004;1025:84–91
  97. Swiercz JM, Kuner R, Offermanns S. Plexin-B1/RhoGEF-mediated RhoA activation involves the receptor tyrosine kinase ErbB-2. J. Cell Biol. 2004;165:869–880
  98. Talukder AH, Vadlamudi R, Mandal M, Kumar R. Heregulin induces expression, DNA binding activity, and transactivating functions of basic leucine zipper activating transcription factor 4. Cancer Res. 2000;60:276–281
  99. Toni N, Buchs PA, Nikonenko I, Bron CR, Muller D. LTP promotes formation of multiple spine synapses between a single axon terminal and a dendrite. Nature. 1999;402:421–425
  100. Uranova N, Orlovskaya D, Vikhreva O, Zimina I, Kolomeets N, Vostrikov V, et al. Electron microscopy of oligodendroglia in severe mental illness. Brain Res. Bull. 2001;55:597–610
  101. Uranova NA, Vostrikov VM, Orlovskaya DD, Rachmanova VI. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr. Res. 2004;67:269–275
  102. Vawter MP, Barrett T, Cheadle C, Sokolov BP, Wood WH, Donovan DM, et al. Application of cDNA microarrays to examine gene expression differences in schizophrenia. Brain Res. Bull. 2001;55:641–650
  103. Vostrikov VM, Uranova NA, Rakhmanova VI, Orlovskaia DD. Lowered oligodendroglial cell density in the prefrontal cortex in schizophrenia. Zh. Nevropatol. Psikhiatr. Im. S. S. Korsakova. 2004;104:47–51
  104. Wain HM, Bruford EA, Lovering RC, Lush MJ, Wright MW, Povey S. Guidelines for human gene nomenclature. Genomics. 2002;79:464–470
  105. Wallin C, Weber SG, Sandberg M. Glutathione efflux induced by NMDA and kainate: implications in neurotoxicity?. J. Neurochem. 1999;73:1566–1572
  106. Wang X, Zhong P, Gu Z, Yan Z. Regulation of NMDA receptors by dopamine D4 signaling in prefrontal cortex. J. Neurosci. 2003;23:9852–9861
  107. Wechsler A, Teichberg VI. Brain spectrin binding to the NMDA receptor is regulated by phosphorylation, calcium and calmodulin. EMBO J. 1998;17:3931–3939
  108. Wedderburn LR, Searle SJ, Rees AR, Lamb JR, Owen MJ. Mapping T cell recognition: the identification of a T cell receptor residue critical to the specific interaction with an influenza hemagglutinin peptide. Eur. J. Immunol. 1995;25:1654–1662
  109. Wei J, Hemmings GP. A study of the combined effect of the CLDN5 locus and the genes for the phospholipid metabolism pathway in schizophrenia. Prostaglandins Leukot. Essent. Fat. Acids. 2005;
  110. Weissert R, Kuhle J, de Graaf KL, Wienhold W, Herrmann MM, Muller C, et al. High immunogenicity of intracellular myelin oligodendrocyte glycoprotein epitopes. J. Immunol. 2002;169:548–556
  111. White JH, McIllhinney RA, Wise A, Ciruela F, Chan WY, Emson PC, et al. The GABAB receptor interacts directly with the related transcription factors CREB2 and ATFx. Proc. Natl. Acad. Sci. U. S. A. 2000;97:13967–13972
  112. Williams NM, Owen MJ. Genetic abnormalities of chromosome 22 and the development of psychosis. Curr. Psychiatry Rep. 2004;6:176–182
  113. Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray RM, Bullmore ET. Meta-analysis of regional brain volumes in schizophrenia. Am. J. Psychiatry. 2000;157:16–25
  114. Wu X, Gu J, Grossman HB, Amos CI, Etzel C, Huang M, et al. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am. J. Hum. Genet. 2006;78:464–479
  115. Wyszynski M, Lin J, Rao A, Nigh E, Beggs AH, Craig AM, et al. Competitive binding of alpha-actinin and calmodulin to the NMDA receptor. Nature. 1997;385:439–442
  116. Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T, et al. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim. Biophys. Acta. 2001;1514:291–302
  117. Yang CR, Chen L. Targeting prefrontal cortical dopamine D1 and N-methyl-d-aspartate receptor interactions in schizophrenia treatment. Neuroscientist. 2005;11:452–470
  118. Yao JK, Reddy RD, van Kammen DP. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs. 2001;15:287–310
  119. Yoo HW, Warner CA, Chen CH, Desnick RJ. Hydroxymethylbilane synthase: complete genomic sequence and amplifiable polymorphisms in the human gene. Genomics. 1993;15:21–29
  120. Yurek DM, Zhang L, Fletcher-Turner A, Seroogy KB. Supranigral injection of neuregulin1-beta induces striatal dopamine overflow. Brain Res. 2004;1028:116–119
  121. Yuste R, Bonhoeffer T. Morphological changes in dendritic spines associated with long-term ynaptic plasticity. Annu. Rev. Neurosci. 2001;24:1071–1089
  122. Zhou M, Zhuang YL, Xu Q, Li YD, Shen Y. VSD: a database for schizophrenia candidate genes focusing on variations. Hum. Mutat. 2004;23:1–7
  123. Zhu BT. CNS dopamine oxidation and catechol-O-methyltransferase: importance in the etiology, pharmacotherapy, and dietary prevention of Parkinson's disease. Int. J. Mol. Med. 2004;13:343–353

PII: S0920-9964(06)00249-0

doi: 10.1016/j.schres.2006.05.023

Schizophrenia Research
Volume 86, Issue 1 , Pages 1-14 , September 2006

Article Tools

* Image Usage & Resolution